AstraZeneca will delay the withdrawal of breast cancer drug Zoladex from the Australian market while it attempts to renegotiate a relisting on the Pharmaceutical Benefits Scheme following fierce patient backlash.

Under the new plan, Zoladex will remain on shelves until May 2027 but PBS prescriptions for the Zoladex 3.6mg monthly implant written by April 30 can still be filled until May 1, 2028.

Zoladex is a drug used by women with endometriosis or hormone receptor-positive metastatic breast cancer. It works by suppressing their sex hormones, which can drive the disease.

When AstraZeneca announced its intention to withdraw its 3.6mg dose from the Australian market for financial reasons, affected patients considered the move as a very real threat to their lives. Some were left so distressed that it was a major contributor to their decision to have their ovaries removed.

The withdrawal was due to happen in November. Not only would the drug be stripped from the PBS, it would be removed from sales entirely.

At the time, the government expressed its disappointment in the decision and said it had made “extensive and sustained efforts to retain the PBS listing” to no avail. Patient groups admonished both sides.

The dispute came amid growing concern that the PBS is not fit for purpose and needs considerable amendments or drug makers will overlook Australia as a favourable market. The drug’s supply has not been affected in similar international markets.

As anger grew, AstraZeneca announced a community access scheme would be rolled out to give patients with no alternative option ongoing access to the drug for free. However, patients and advocates said the pledge provided no guarantee of supply and could be reneged as easily as it was made.

The Australian can now reveal AstraZeneca and the government have been locked in closed-door negotiations to try to get Zoladex relisted on the PBS at a new price. However, the drug maker’s first application, made just weeks ago, was rejected.

“The Pharmaceutical Benefits Advisory Committee was unable to grant a price adjustment that would have allowed the continued PBS reimbursement of this medicine,” said Marie Guillet, country president, AstraZeneca Australia and New Zealand.

The Australian understands the company is highly likely to soon make a new application, which is why it has extended the drug’s supply by six months. AstraZeneca has consistently said its decision is based on financial pressure from multiple fronts.

“Zoladex monthly (3.6mg) has decades of clinical use in Australia and around the world,” Dr Guillet said. “It is, however, expensive to manufacture and the accumulation of years of inflation has increased the manufacturing cost, despite productivity improvements. On the other hand, the price is less than half what it was when first listed in 1991.

“Universal and equitable access to medicines is critical to the continued health of Australians. The PBS will require appropriate funding to ensure Australians are not denied access to medicines.”

The federal government last week announced it would make the drug Triptorelin, sold as Dishereline, available on the PBS from October for a range of conditions including breast cancer, endometriosis and uterine fibrosis. The drug is considered an alternative to Zoladex.

Health Minister Mark Butler said women should be able to access the medicines they need without barriers and that he would “continue to make sure women have access to affordable treatment, more choice and better care”.

Australians risk losing access to world’s best drugs, clinical trialsAustralians risk losing access to world’s best drugs, clinical trials

The nation faces being cut out of lifesaving treatments and cutting-edge research, say top doctors and pharmaceutical companies, who blame unrealistic prices and global disruption.

Mounjaro’s scathing rejection explains why drug access is failingMounjaro’s scathing rejection explains why drug access is failing

Eli Lilly warns more medicines won’t get subsidised in Australia as hundreds of thousands of patients are forced to pay full price for the diabetes treatment.

Why Xavier needs to go to the US for his cancer drugsWhy Xavier needs to go to the US for his cancer drugs

The eight-year-old and his family will travel to America next month to pick up medicine that is subsidised in Australia – but not for him.

‘An afterthought’: Patients left waiting in drug price war‘An afterthought’: Patients left waiting in drug price war

Health Minister Mark Butler has tied long-overdue drug pricing reforms to July negotiations with pharma, leaving Australia’s medicines approval system under pressure

Patients ‘who could be cured’ are dying in NZ’s drug-funding crisisPatients ‘who could be cured’ are dying in NZ’s drug-funding crisis

New Zealanders have faced years of being locked out of access to new medicines. It’s a warning for Australia, says a leading doctor.

‘Early menopause’: women risk drastic measures as cancer drug cut‘Early menopause’: women risk drastic measures as cancer drug cut

Mother of two and cancer patient Aimee Glen says the decision by a pharmaceutical giant to remove a crucial drug from Australian shelves is devastating.

Australia is not ready for the future of cancer careAustralia is not ready for the future of cancer care

Huge leaps in treatments, partly driven by AI, may not be available here if we let innovation slide, says a leader in the field.

‘Rationing system’ denies patients next-gen drugs‘Rationing system’ denies patients next-gen drugs

Australia has a proud history of negotiating hard to get cheaper drugs, but there are fears the bargaining could come with nasty side effects.

Australian lives on the line in global battle over drug pricingAustralian lives on the line in global battle over drug pricing

Our Pharmaceutical Benefits Scheme was designed for a different era. Now it’s coming under huge pressure as worldwide disruption in medicines threatens patient access – and lives.

Our PBS must evolve or risk being overwhelmed by costly new drugsOur PBS must evolve or risk being overwhelmed by costly new drugs

Australia’s affordable medicines scheme was designed for another era. Now we need to make it sustainable for a market that is undergoing global change.

NZ’s in a free fall on medicines. Can we avoid the same fate?NZ’s in a free fall on medicines. Can we avoid the same fate?

Approvals are so slow that some drugs, even for common conditions, are not given a tick for years after being available elsewhere. Australia must take note.

Drug price disputes swamp medicine approvals committeeDrug price disputes swamp medicine approvals committee

The body that’s supposed to approve new drugs for listing on the PBS is instead forced to deal with pharma companies refusing to accept Australia’s prices.

Multiple sclerosis drugs saved from PBS pricing axeMultiple sclerosis drugs saved from PBS pricing axe

The price paid for key MS treatments Ocrevus and Kesimpta sparked a stoush between drug companies and the government. Health Minister Mark Butler has now received crucial advice.

Kelly thought she was dying as ‘sinister’ Crohn’s disease flaredKelly thought she was dying as ‘sinister’ Crohn’s disease flared

Australia, where inflammatory bowel disease is prevalent, is locked out of some of the best treatment advances.

The medicines Australian patients are missing out onThe medicines Australian patients are missing out on

Australia’s Pharmaceutical Benefits Scheme is facing its biggest challenge – and a new report reveals the drugs we are already being denied.

Teacher pays $20k for cancer drug Australia won’t fundTeacher pays $20k for cancer drug Australia won’t fund

Craig’s rare disease means he must crowdfund to afford his medicine as the ‘orphan drugs’ program to help patients like him is failing, a new report finds.

Why you won’t be getting Wegovy on the PBS any time soonWhy you won’t be getting Wegovy on the PBS any time soon

The GLP-1 drug was recommended for listing on the Pharmaceutical Benefits Scheme for certain patients over seven months ago. Now the landmark deal has stalled.

‘Can hardly walk’, yet this doctor’s patients can’t get weight-loss drugs‘Can hardly walk’, yet this doctor’s patients can’t get weight-loss drugs

The failure so far to list Wegovy on Australia’s PBS has become a case study in inequity as those with severe obesity struggle to access treatment.

Butler says weight-loss meds must be listed on the PBSButler says weight-loss meds must be listed on the PBS

Responding to stories featured in The Australian, the Health Minister says the new class of weight-loss drugs are too important not to be subsidised for those who need them.

Keytruda now affordable to thousands more cancer patientsKeytruda now affordable to thousands more cancer patients

The multi-tumour listing of the key immunotherapy drug on the PBS ends a devastating inequity in public subsidisation, giving 10,000 patients lifesaving access for as little as $25.

In Abby’s name: sister joins push for better access to medicinesIn Abby’s name: sister joins push for better access to medicines

A 29-year-old mother was told Australia had nothing to offer in her fight against advanced pancreatic cancer. Her sister says the family’s ordeal is far from unique.

A separate three-monthly Zoladex implant, for men with prostate cancer, remains unaffected by any of the changes to supply. However, the drug has now been approved for use for the management of oestrogen receptor-positive early and advanced breast cancer in pre- and perimenopausal women.

A decision is pending on whether the PBAC will recommend it for PBS listing for those conditions. With alternatives now available, AstraZeneca’s community access program to the 3.6mg Zoladex implant will not proceed.

Want to get healthy? Sign up to our free newsletter for trusted tips on diet, fitness, medical breakthroughs and guidance on sex and relationships here.